🔗 Share this article World Health Organization Raises Concern Over Severe Shortage of Weight-Loss Injections Less than a tenth of people that would benefit from GLP-1 drugs such as Wegovy can access them, states the global health agency as it issues its initial recommendations on the therapies. Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer availability to GLP-1 medication. According to projections, more than two billion will be obese by 2030 if no action is taken. "The new guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major obstacles to widespread access to the injections that can aid individuals in losing considerable body mass, explains the agency. Weight-Loss Drug Scarcity Despite the present best projected scenario, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, per the WHO. The guideline calls on nations and manufacturers to increase availability, by measures including patent sharing. A patent on the active ingredient – the main component of the drug Wegovy – is due to expire in a number of countries in 2026. The Way Obesity Injections Operate These medications mimick a body's own hormone to reduce digestion speed, suppress the appetite and increase satiety so people reduce food intake. People usually see weight reduction after several weeks of commencing the regular doses. Research suggests users may put most of the weight back on a year later of halting the treatment, because their usual appetite return. To be carrying excess weight raises your risk for experiencing health problems, such as type 2 diabetes, heart disease, brain attack, and certain malignancies. Excess weight affects individuals in every country and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
Less than a tenth of people that would benefit from GLP-1 drugs such as Wegovy can access them, states the global health agency as it issues its initial recommendations on the therapies. Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer availability to GLP-1 medication. According to projections, more than two billion will be obese by 2030 if no action is taken. "The new guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major obstacles to widespread access to the injections that can aid individuals in losing considerable body mass, explains the agency. Weight-Loss Drug Scarcity Despite the present best projected scenario, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, per the WHO. The guideline calls on nations and manufacturers to increase availability, by measures including patent sharing. A patent on the active ingredient – the main component of the drug Wegovy – is due to expire in a number of countries in 2026. The Way Obesity Injections Operate These medications mimick a body's own hormone to reduce digestion speed, suppress the appetite and increase satiety so people reduce food intake. People usually see weight reduction after several weeks of commencing the regular doses. Research suggests users may put most of the weight back on a year later of halting the treatment, because their usual appetite return. To be carrying excess weight raises your risk for experiencing health problems, such as type 2 diabetes, heart disease, brain attack, and certain malignancies. Excess weight affects individuals in every country and was associated with 3.7 million deaths worldwide in 2024, per the WHO.